Baxter International announced it will form a R&D center in Cambridge, Massachusetts for its new biopharmaceutical company, Baxalta.

NIH seeks new therapeutic products to bolster the protective properties of vaccines.

AMAG Pharmaceuticals announced the acquisition of women?s health brand, Lumara Health, for $675 million, with an additional contingency of up to $350 million.

Johnson & Johnson announced the acquisition of Alios BioPharma to expand their portfolio of therapeutics for viral infections.

A new Thomson Reuters BioWorld report outlines the more than 700 biosimilars that are currently in development and the emerging business opportunities that exist in the biopharmaceutical space.

SCHOTT will present the adaptiQ ready-to-use vials, syriQ prefilled syringes, and the TopPac Polymer syringes at CPhI Worldwide 2014 in Paris.

Quality is a matter of culture more than metrics. In this opinion article, the author presents arguments for an FDA Dean's List as a means to nurture a quality culture within the industry.

Partnership is awarded for licensing of low-cost vaccine for the treatment of bacterial meningitis.

In response to the Ebola outbreak, EMA has started reviewing Ebola treatments in the development pipeline.

CHMP has recommended 15 new medicines for approval and three extensions of indication.

International Organization for Standardization's environmental management standard 14001 has entered the draft stage, allowing public commentary on revisions.

Global Controlled Release Alliance, a partnership between Dow Pharma & Food Solutions and Colorcon, will present METHOCEL DC2 compressible hydroxypropyl methylcellulose at CPhI Worldwide 2014.

NIH continues funding for tissue chips to be used in the development of therapeutics.

USP expresses its support for a consensus-based global approach to the naming of biologics.

FDA report details risk mitigation projects.

Formulation will utilize Catalent?s OSDrC OptiDose multicore drug-delivery platform.

Meeting increasing expectations and escalating regulatory requirements to protect patients.

Acorda Therapeutics acquired Civitas Therapeutics for $525 million, giving Acorda all the rights to CVT-301, a Phase III candidate for off episodes of Parkinson's disease.

The campaign supports pharmaceutical growth in India and serves to highlight the value proposition that Indian pharmaceuticals present.

AstraZeneca's global biologics research group, MedImmune, received FDA Fast Track designation for MEDI3902, for the prevention of nosocomial pneumonia.

AdPack is an efficient, economical, and safe solution for the protection of moisture-sensitive pharmaceuticals, such as tablets and capsules, inside the packaging.

In its 2014 annual report from CPhI Worldwide, industry experts suggest that the pharmaceutical industry needs an evolutionary approach to remain sustainable in the longer term.

Avalon Ventures and GSK add two more companies to their launch list of early-stage life-science companies.

Almac Group recently appointed two key positions in marketing: Market Development Director, and Senior Market Insight Director.

DuPont Nutrition & Health has added a new pharmaceutical excipient to the portfolio of ingredients for CPhI Worldwide 2014, in Paris this October.

Alchem International announced that it will continue to market and support Tropane Alkaloid APIs despite earlier reports.

I Holland, in collaboration with the University of Nottingham and experts from the Laboratory of Biophysics and Surface Analysis, United Kingdom, recently completed a two-year tableting science anti-stick research (TSAR) project, which sought to understand why certain formulations stick to tablet tooling.

CALIXAR and VirPath use new manufacturing techniques to create a vaccine for the pandemic flu, influenza A (H1N1), available in 2015.